Trials / Unknown
UnknownNCT06245876
Lung EpiCheck Biomarkers Development Study
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 6,000 (estimated)
- Sponsor
- Nucleix Ltd. · Industry
- Sex
- All
- Age
- 20 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
This study is part of the development of a non-invasive lung cancer screening test which aim to identify early-stage lung cancer in patients at high risk for lung cancer.
Detailed description
This is a prospective, multi-center, observational nonsignificant risk study aimed to collect blood and clinical data from primary lung cancer and control subjects to characterize various biomarkers that will discriminate between lung cancer and control subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Blood collection | Blood collection |
Timeline
- Start date
- 2022-05-17
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
- First posted
- 2024-02-07
- Last updated
- 2024-02-12
Locations
10 sites across 4 countries: United States, Hungary, Israel, Netherlands
Source: ClinicalTrials.gov record NCT06245876. Inclusion in this directory is not an endorsement.